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Fulvestrant (‘Faslodex’) is a new type of endocrine treatment – an oestrogen receptor (ER) antagonist that downregulates the ER and
has no agonist effects. Early efficacy data from phase I/II trials have demonstrated fulvestrant to be effective and well tolerated. Two
randomised phase III trials have compared the efficacy of fulvestrant and the aromatase inhibitor, anastrozole, in postmenopausal
women with advanced breast cancer progressing on prior endocrine therapy. Fulvestrant (intramuscular injection 250mgmonth
 1)
was found to be at least as effective as anastrozole (orally 1mgday
 1) for time to progression (5.5 vs 4.1 months, respectively (hazard
ratio (HR): 0.95; 95.14% confidence interval (CI), 0.82–1.10; P¼0.48)) and objective response 19.2 vs 16.5%, respectively; treatment
difference 2.75%; 95.14% CI,  2.27 to 9.05%; P¼0.31). More recently, fulvestrant has also been shown to be noninferior to
anastrozole in terms of overall survival, with median time to death being 26.4 months in fulvestrant-treated patients and 24.2 months
in those treated with anastrozole (HR: 0.97; 95% CI, 0.78–1.21; P¼0.82). In a further randomised phase III trial, fulvestrant was
compared with tamoxifen as first-line therapy for advanced disease in postmenopausal women. In the overall population, efficacy
differences favoured tamoxifen and noninferiority of fulvestrant could not be ruled out. In the prospectively defined subset of patients
with ER-positive and/or progesterone receptor-positive disease, there was no statistically significant difference between fulvestrant
and tamoxifen. This paper reviews the efficacy and tolerability results from these trials.
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Fulvestrant (‘Faslodex’) is a new type of endocrine treatment – an
oestrogen receptor (ER) antagonist with no agonist effects
(Wakeling et al, 1991). In trials designed to establish the biological
activity of fulvestrant, conducted in postmenopausal patients with
previously untreated breast cancer, fulvestrant produced signifi-
cant reductions in cellular levels of the ER, the oestrogen-
dependent progesterone receptor (PgR), and the tumour cell
proliferation marker Ki67 (DeFriend et al, 1994; Robertson et al,
2001).
The favourable results obtained with fulvestrant in early trials
led to the initiation of a phase III clinical trial programme
conducted in postmenopausal women with hormone-sensitive
advanced breast cancer. As second-line therapy, fulvestrant was
compared with the third-generation aromatase inhibitor (AI)
anastrozole. The results from these trials have led to the approval
of fulvestrant for the treatment of postmenopausal women with
hormone-sensitive advanced breast cancer following progression
on prior endocrine therapy. As first-line hormonal therapy,
fulvestrant has also been compared with tamoxifen.
PHASE I/II STUDIES
Clinical activity
Initial efficacy data for fulvestrant in 19 postmenopausal patients
with tamoxifen-resistant advanced breast cancer demonstrated
that fulvestrant produced a clinical benefit (CB, complete
responseþpartial responseþstable disease for a duration X24
weeks) rate of 69% with a median duration of response (DoR) of 25
months (Howell et al, 1996a). In this study, CB was observed in six
of the nine (67%) women who had progressed on prior tamoxifen
therapy and in seven of the 10 (70%) women who had relapsed
after treatment with tamoxifen as adjuvant therapy (Howell et al,
1996a). As predicted from preclinical data (Hu et al, 1993), these
findings demonstrated that fulvestrant was not crossresistant with
tamoxifen in the clinical setting.
Tolerability
Fulvestrant was well tolerated with no serious drug-related adverse
events (AEs) reported and no patients withdrawn due to toxicity.
Local injection-site reactions were also uncommon (DeFriend et al,
1994; Howell et al, 1996a). In both studies, fulvestrant was
associated with only minor systemic AEs, and the only AE reported
by more than one patient was headache (six of 37 patients, 16.2%)
*Correspondence: Dr I Vergote;
E-mail: ignace.vergote@uz.kuleuven.ac.be
British Journal of Cancer (2004) 90(Suppl 1), S11–S14
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com(DeFriend et al, 1994). Fulvestrant had no effect on serum
gonadotrophin, sex hormone-binding globulin levels (DeFriend
et al, 1994; Howell et al, 1996a) or serum lipids (Howell et al,
1996a). Administration of fulvestrant was not associated with any
alteration in the frequency of pre-existing night sweats or hot
flushes, and none of these AEs were initiated during fulvestrant
treatment (Howell et al, 1996a).
PHASE III STUDIES: FULVESTRANT VS
ANASTROZOLE
Two phase III trials (0020 and 0021) were conducted to compare
the efficacy and tolerability of fulvestrant vs anastrozole in
postmenopausal women with hormone-sensitive advanced breast
cancer (Howell et al, 2002; Osborne et al, 2002). The majority of
patients (X95%) had received prior treatment with tamoxifen, but
a few had previously been treated with megestrol acetate, goserelin
or a selective ER modulator (SERM; droloxifene, idoxifene or
raloxifene).
Trial 0020 was a randomised, open-label trial conducted in
Europe, South Africa and Australia. Trial 0021 was a double-blind,
double-dummy study conducted in North America. The design of
both trials was identical, except for a slight variation in the dosage
delivery regimen, which was due to variations in clinical practice at
that time between the US and the rest of the world. In trial 0020,
fulvestrant 250mg was administered as a 1 5ml intramuscular
(i.m.) injection and in trial 0021 as 2 2.5ml i.m. injections.
Efficacy
In trial 0020, after a median follow-up of 14.4 months, the median
time to progression (TTP) was 5.5 months for fulvestrant and 5.1
months for anastrozole (HR: 0.98; 95.14% CI, 0.80–1.21; P¼0.84)
(Figure 1A). The objective response (OR) rate was 20.7% for
fulvestrant and 15.7% for anastrozole (odds ratio: 1.38; 95.14% CI,
0.84–2.29; P¼0.20). To obtain more complete information on
DoR, further follow-up was performed. At a median follow-up of
22.6 months, the median DoR (from randomisation to progression
in responding patients) was 15.0 months for fulvestrant and 14.5
months for anastrozole (Figure 2A) (Howell et al, 2002). A survival
analysis from this study showed that fulvestrant was noninferior to
anastrozole with respect to overall survival, with the median time
to death being 26.4 months in fulvestrant-treated patients and 24.2
months in those treated with anastrozole (HR: 0.97; 95% CI, 0.78–
1.21; P¼0.82) (Howell et al, 2003).
In trial 0021, patients were followed up for a median of 16.8
months. The median TTP was 5.4 months for fulvestrant and 3.4
months for anastrozole (HR: 0.92; 95.14% CI, 0.74–1.14; P¼0.43)
(Figure 1B). OR was 17.5% for both fulvestrant and anastrozole
(odds ratio: 1.01; 95.14% CI, 0.59–1.73; P¼0.96). After an
extended median follow-up of 21.3 months, the median DoR was
19.0 months for fulvestrant and 10.8 months for anastrozole
(Figure 2B) (Osborne et al, 2002).
Both trials were prospectively designed to allow combination of
results. After a median follow-up of 15.1 months, combined data
from 851 patients showed a median TTP of 5.5 and 4.1 months
(HR: 0.95; 95.14% CI, 0.82–1.10; P¼0.48) and OR rates of 19.2 and
16.5% for fulvestrant and anastrozole, respectively (difference in
response rates: 2.75%; 95.14% CI  2.27 to 9.05%; P¼0.31)
(Robertson et al, 2003). Analysis of DoR from an extended median
follow-up of 22.1 months showed the median DoR to be 16.7
months for fulvestrant and 13.7 months for anastrozole (Robertson
et al, 2003). In a further analysis of DoR (mean DoR) that included
all randomised patients (defined for responders as the onset of
response to disease progression, and for nonresponders as zero),
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Figure 1 Kaplan–Meier estimates of TTP for fulvestrant vs anastrozole:
(A) trial 0020, (B) trial 21 (Howell et al, 2002; Osborne et al, 2002).
Reprinted with permission from the American Society of Clinical Oncology.
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Figure 2 Kaplan–Meier estimates of DoR for fulvestrant vs anastrozole
(responding patients only): (A) trial 0020, (B) trial 0021 (Howell et al,
2002; Osborne et al, 2002). Reprinted with permission from the American
Society of Clinical Oncology.
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(ratio of average response durations: 1.30; 95% CI, 1.13–1.50;
Po0.01) (Robertson et al, 2003).
Of the 851 patients in the combined analyses of both trials,
visceral metastases were present in 381 (44.8%) patients. After a
median follow-up of 15.1 months, OR and CB were similar between
fulvestrant and anastrozole in patients with visceral metastases
(OR: 15.7 vs 13.2%; CB: 38.2 vs 37.4% for fulvestrant vs anastrozole,
respectively) and in those with no visceral metastases (OR: 21.9 vs
19.3%; CB: 47.6 vs 43.8%) (Mauriac et al, 2003). A further
retrospective analysis of the combined data from these trials
evaluated response to subsequent therapy in patients gaining CB
or no CB (stable disease o24 weeksþdisease progression) from
fulvestrant treatment. Of the 54 patients deriving CB from
fulvestrant, who also received further endocrine therapy, 25
patients derived CB from subsequent treatment. Similarly, 18 of
the 51 patients who did not derive CB from fulvestrant went on to
gain CB from subsequent endocrine treatment, demonstrating that
patients may retain sensitivity to other endocrine agents after
progression on fulvestrant (Vergote et al, 2003).
Tolerability
In both trials, fulvestrant was well tolerated. At the outset of the
trials, seven AEs were considered relevant to endocrine therapy
and were predefined for statistical analysis. These were: gastro-
intestinal disturbances, hot flushes, vaginitis, weight gain,
thromboembolic disease, urinary tract infection and joint dis-
orders (including arthralgia, arthrosis and arthritis). In the
combined analysis, the incidences of these predefined AEs were
similar for fulvestrant and anastrozole, except joint disorders, the
incidence of which was significantly lower for fulvestrant
compared with anastrozole (5.4 vs 10.6%; P¼0.0036) (Table 1).
The most common AEs in both treatment groups, irrespective of
the relationship to study medication, were nausea (26.0 vs 25.3%
for fulvestrant and anastrozole, respectively), asthenia (22.7 vs
27.0%), pain (18.9 vs 20.3%), vasodilatation (17.7 vs 17.3%) and
headache (15.4 vs 16.8%). Withdrawals due to drug-related AEs
were reported in 0.9% of patients treated with fulvestrant and in
1.2% of those treated with anastrozole (Robertson et al, 2003).
Quality of life
The maintenance of quality of life (QoL) is an important
consideration when making treatment choices for patients with
advanced breast cancer. In both phase III trials, the QoL was
assessed using the Functional Assessment of Cancer Therapy –
Breast (FACT-B) questionnaire. This tool is a sensitive measure for
evaluating physical, functional, social and emotional well-being
and comprises the FACT-G ‘general’ QoL tool for cancer patients
plus the Breast Cancer Subscale (Cella et al, 1993; Brady et al,
1997). The treatment outcome index (TOI), within the FACT-B
questionnaire, is the sum of the well-being and breast cancer
subscales. In both trials, QoL was maintained over time with no
statistically significant difference between anastrozole and fulves-
trant (Howell et al, 2002; Osborne et al, 2002).
PHASE III STUDY: FULVESTRANT VS TAMOXIFEN
Fulvestrant 250mg (delivered as a once-monthly 5ml i.m.
injection) has been compared with tamoxifen 20mg (orally, once
daily) in a trial conducted in postmenopausal women with ER-
positive and/or PgR-positive or ER/PgR-unknown advanced breast
cancer who had not been treated with prior endocrine therapy or
chemotherapy for advanced disease. This study was a double-
blind, randomised, parallel-group, double-dummy trial conducted
at 171 centres in 26 countries throughout the world, including
Europe, North and South America, Africa and Australia.
Of the 587 patients who were randomised to treatment, 78% of
patients in the fulvestrant group and 75.2% of those in the
tamoxifen group had received no prior tamoxifen in the adjuvant
setting.
Efficacy
In the overall population, after a median follow-up of 14.5 months,
there was no significant difference between the two treatments for
TTP (median TTP: 6.8 vs 8.3 months for fulvestrant and tamoxifen,
respectively; HR: 1.18; 95% CI, 0.98–1.44; P¼0.09). However,
observed differences in other efficacy end points favoured
tamoxifen and noninferiority of fulvestrant could not be demon-
strated (Robertson et al, 2002).
In a prospectively planned analysis of patients with ER-positive
and/or PgR-positive tumours (78.9% of fulvestrant-treated patients
and 77.4% of tamoxifen-treated patients), in the population
intended for treatment with endocrine therapy, the TTP was
similar between the two treatments (median TTP: 8.2 vs 8.3 months
for fulvestrant and tamoxifen, respectively; HR: 1.10; 95% CI,
0.89–1.36; P¼0.39). The OR rate in this hormone receptor-
positive subgroup was 33.2% for fulvestrant and 31.1% for
tamoxifen (Robertson et al, 2002).
Previous studies have suggested that patients with ER-positive
and PgR-positive breast tumours have a more active ER and have
demonstrated that these patients are more likely to benefit from
endocrine therapy compared with patients with ER-positive/PgR-
negative tumours (Wittliff, 1984; Jakesz et al, 2002; Bardou et al,
2003). In an exploratory analysis of only those patients with ER-
positive and PgR-positive tumours (approximately 42% of the trial
population), the median TTP was 11.4 months for fulvestrant and
8.5 months for tamoxifen (HR: 0.85; 95% CI, 0.63–1.15; P¼0.31)
and OR was significantly higher for fulvestrant compared with
tamoxifen (44.3 vs 29.8%; P¼0.02). Furthermore, 20 out of 35
patients who responded to first-line treatment with fulvestrant and
provided follow-up information on subsequent treatments re-
tained sensitivity to subsequent therapies including anastrozole,
letrozole, fadrozole, tamoxifen and megestrol acetate (Howell and
Robertson, 2002).
Tolerability
Both treatments were well tolerated. The incidence of prospectively
defined AEs of gastrointestinal disturbances (nausea, vomiting,
diarrhoea and constipation), vaginitis and thromboembolic dis-
ease was similar between fulvestrant and tamoxifen. However, the
incidence of hot flushes was lower in patients treated with
fulvestrant compared with those treated with tamoxifen
(P¼0.0501).
Table 1 Incidences of predefined adverse events for fulvestrant vs
anastrozole (combined analysis) (Robertson et al, 2003)
Fulvestrant
(n¼423)
Anastrozole
(n¼423)
n % n % P-value
Gastrointestinal disturbances 196 46.3 185 43.7 0.53
Hot flushes 89 21.0 87 20.6 0.91
Joint disorders 23 5.4 45 10.6 0.0036
Thromboembolic disease 15 3.5 17 4.0 0.68
Urinary tract infection 31 7.3 18 4.3 0.06
Vaginitis 11 2.6 8 1.9 0.51
Weight gain 4 0.9 7 1.7 0.35
Copyright r (2003) American Cancer Society. Reprinted with the permission of
Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.
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Two pivotal phase III trials have demonstrated that fulvestrant is
well tolerated and is at least as effective as the third-generation AI
anastrozole in patients with advanced breast cancer who have
progressed on prior endocrine therapy. A prospectively planned
combined analysis from these trials demonstrated that fulvestrant
is at least as effective as anastrozole with respect to TTP, OR and
DoR. Although investigations of the 1 5ml and the 2 2.5ml
injections have demonstrated that the pharmacokinetic profiles of
these doses are comparable (Robertson and Harrison, 2003), recent
adjustments in US clinical practice have meant that fulvestrant is
now generally administered as a 1 5ml injection. This single
parenteral mode of administration may offer potential benefits in
terms of patient compliance (particularly for elderly patients)
compared with the oral dosing regimens of most other endocrine
therapies.
As first-line treatment of advanced breast cancer in postmeno-
pausal women with ER-positive and/or PgR-positive tumours,
fulvestrant appears to have a similar efficacy to tamoxifen. In
patients with ER-positive and PgR-positive tumours, a subset
likely to be sensitive to the positive benefits of endocrine
treatments, a retrospectively derived analysis of the data was
suggestive of a possible benefit for fulvestrant compared with
tamoxifen in terms of OR. However, these latter findings require
further investigation so that the patient population most likely to
benefit from fulvestrant in the first-line setting can be established.
Fulvestrant is the only ER antagonist that has demonstrated
unequivocal efficacy in patients with tamoxifen-resistant advanced
breast cancer. Although other antioestrogens, that is, some of the
SERM-like compounds, have shown limited efficacy in the first-
line treatment of advanced breast cancer, they are relatively
ineffective in patients who are resistant to tamoxifen (Stenbygaard
et al, 1993; Pyrhonen et al, 1994; Howell et al, 1996b; Buzdar and
Hortobagyi, 1998). This provides evidence that fulvestrant has a
novel mode of action and illustrates that it is an appropriate
therapeutic choice for patients with hormone-sensitive advanced
breast cancer who have received prior treatment with endocrine
therapy (including tamoxifen).
In summary, as second-line therapy for postmenopausal
women with ER-positive and/or PgR-positive advanced breast
cancer who have progressed on prior endocrine treatment,
fulvestrant is clearly an effective therapy that offers equal efficacy
to anastrozole.
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